Fig. 4

Performance of other mutation panels for predicting the efficacy of immunotherapy in the test datasets. a Kaplan–Meier curves of progression-free survival (PFS) for 59 advanced lung adenocarcinoma (LUAD) patients in the Matthew dataset, using the 324-gene panel. b Kaplan–Meier curves of PFS for 29 advanced LUAD patients in the Rizvi dataset, using the 324-gene panel. c Kaplan–Meier curves of PFS for 59 patients in the Matthew dataset, using the 341-gene panel. d Kaplan–Meier curves of PFS for 29 patients in the Rizvi dataset, using the 341-gene panel. e Kaplan–Meier curves of PFS for 59 patients in the Matthew dataset, using the LUAD-specific 24-gene panel. The p value was determined using log-rank test. The hazard ratio (HR) and 95% confidence interval (CI) were determined using univariate Cox regression models